These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7232658)

  • 21. Altered receptor sensitivity following chronic drug administration in man: the tardive dyskinesia model [proceedings].
    Rubovits R
    Psychopharmacol Bull; 1977 Jan; 13(1):49-50. PubMed ID: 402011
    [No Abstract]   [Full Text] [Related]  

  • 22. Tardive dyskinesia and essential fatty acids.
    Vaddadi K; Hakansson K; Clifford J; Waddington J
    Int Rev Psychiatry; 2006 Apr; 18(2):133-43. PubMed ID: 16777667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disappearance of tardive dyskinesia during catatonic stupor.
    Assmann VC; van Woerkom TC
    Acta Psychiatr Scand; 1987 Aug; 76(2):217-8. PubMed ID: 3673646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [What is the connection between Parkinson disease and tardive dyskinesia?].
    Gunne LM; Andrén PE
    Lakartidningen; 1994 Aug; 91(34):2953-5. PubMed ID: 7990538
    [No Abstract]   [Full Text] [Related]  

  • 25. Structural change in tardive dyskinesia.
    Mattes J
    Am J Psychiatry; 1977 Dec; 134(12):1448. PubMed ID: 920861
    [No Abstract]   [Full Text] [Related]  

  • 26. Brain iron, dopamine receptor sensitivity, and tardive dyskinesia.
    Blinder BJ; Goodman S; Youdim MB
    Am J Psychiatry; 1986 Feb; 143(2):277-8. PubMed ID: 2868669
    [No Abstract]   [Full Text] [Related]  

  • 27. Tardive dyskinesia: a clinical test of the supersensitivity hypothesis.
    Bowers MB; Moore D; Tarsy D
    Psychopharmacology (Berl); 1979 Mar; 61(2):137-41. PubMed ID: 220654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pathophysiology and therapy of L-Dopa-induced dyskinesia].
    Hadj Tahar A; Bézard E; Grondin R; Gross CE; Bédard PJ
    Rev Neurol (Paris); 2003 Dec; 159(12):1125-42. PubMed ID: 14978413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GABAmimetic treatments for tardive dyskinesia: efficacy and mechanism.
    Tamminga CA; Thaker GK; Nguyen JA
    Psychopharmacol Bull; 1989; 25(1):43-6. PubMed ID: 2672071
    [No Abstract]   [Full Text] [Related]  

  • 30. [Neuroleptics and nicotine].
    Erdmann R
    Psychiatr Prax; 1995 Nov; 22(6):223-7. PubMed ID: 8570751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of tardive dyskinesia by estrogen: neurochemical studies in an animal model.
    Gordon JH; Diamond BI
    Trans Am Neurol Assoc; 1979; 104():97-100. PubMed ID: 553438
    [No Abstract]   [Full Text] [Related]  

  • 32. Symptomatic treatment of tardive dyskinesia: a word of caution.
    Kucharski LT; Unterwald EM
    Schizophr Bull; 1981; 7(4):571-3. PubMed ID: 6798690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Physiopathology and treatment of tardive dyskinesia].
    Cai N; Song TS
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):252-5. PubMed ID: 3000711
    [No Abstract]   [Full Text] [Related]  

  • 34. GABA system: clinical research and treatment of tardive dyskinesia.
    Thaker GK; Hare TA; Tamminga CA
    Mod Probl Pharmacopsychiatry; 1983; 21():155-67. PubMed ID: 6419061
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug-induced movement disorders.
    Gershanik OS
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):369-76. PubMed ID: 8099509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tardive dyskinesia and thioridazine.
    Arch Gen Psychiatry; 1984 Apr; 41(4):414-6. PubMed ID: 6703859
    [No Abstract]   [Full Text] [Related]  

  • 38. Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems.
    Miczek KA; Fish EW; De Bold JF; De Almeida RM
    Psychopharmacology (Berl); 2002 Oct; 163(3-4):434-58. PubMed ID: 12373445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dyskinesia. Research and treatment.
    Psychopharmacology Suppl; 1985; 2():1-230. PubMed ID: 3858798
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of the role of cortical GABA in the induction of abnormal involuntary movements in rats.
    Robin M; Palfreyman M; Zraika M; Schechter P
    Adv Biochem Psychopharmacol; 1981; 29():37-44. PubMed ID: 7257935
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.